Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind, Placebo-Controlled, Randomized Controlled Trial
RCT 300 outpatients in China, showing improved recovery with Jinhua Qinggan treatment, but no significant difference in viral clearance or radiographic findings. Jinhua Qinggan includes quercetin, rutin, luteolin, wogonin, myricetin, ursolic acid, chrysoeriol, glabridin, stigmasterol, and kaempferol.
This study is excluded in meta
analysis:
combination of several ingredients with unclear dosage.
risk of no symptoms decrease ≥30%, 80.6% lower, RR 0.19, p < 0.001, treatment 26 of 150 (17.3%), control 134 of 150 (89.3%), NNT 1.4.
|
risk of no symptoms decrease ≥70%, 58.1% lower, RR 0.42, p < 0.001, treatment 62 of 150 (41.3%), control 148 of 150 (98.7%), NNT 1.7.
|
risk of no symptoms decrease ≥90%, 35.8% lower, RR 0.64, p < 0.001, treatment 95 of 150 (63.3%), control 148 of 150 (98.7%), NNT 2.8.
|
risk of no radiographic improvement, 0.7% lower, RR 0.99, p = 1.00, treatment 112 of 128 (87.5%), control 111 of 126 (88.1%), NNT 168.
|
risk of no viral clearance, 8.1% higher, RR 1.08, p = 0.48, treatment 93 of 150 (62.0%), control 86 of 150 (57.3%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Shah et al., 20 May 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Pakistan, preprint, 10 authors, study period 22 September, 2020 - 23 August, 2021, trial
NCT04723524 (history).
Contact:
raza.shah@iccs.edu, liuqingquan@bjzhongyi.com, dennislam@hkcmer.com.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.05.16.22275074; this version posted May 20, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Jinhua Qinggan Granules for Nonhospitalized COVID-19 Patients: a Double-Blind,
Placebo-Controlled, Randomized Controlled Trial
Muhammad Raza Shah*1, Samreen Fatima1, Sehrosh Naz Khan1, Shafiullah1, Gulshan Himani2,
Kelvin Wan3, Timothy Lin3, Johnson Y.N. Lau4, Qingquan Liu*5, Dennis S.C. Lam*3,4
1] Center for Bioequivalence Studies and Clinical Research, Dr. Panjwani Center for Molecular
Medicine and Drug Research, International Center for Chemical and Biological Sciences,
University of Karachi, Karachi-75270,
2] The Indus Hospital Karachi, Plot C-76, Sector 31/5, Opposite Korangi Crossing, Darussalam
Society Sector 39, Karachi, Sindh, Pakistan
3] Hong Kong Alliance of Integrated Medicine Against Covid, Hong Kong
4] School of Chinese Medicine of Hong Kong, Baptist University, Hong Kong
5] Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing,
People’s Republic of China
*E-mail address for correspondence
Muhammad Raza Shah: raza.shah@iccs.edu ,
Qingquan Liu: liuqingquan@bjzhongyi.com,
Dennis S.C. Lam: dennislam@hkcmer.com
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2022.05.16.22275074; this version posted May 20, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Abstract
Background: Key findings from the World Health Organization Expert Meeting on Evaluation
of Traditional Chinese Medicine in treating COVID-19 reported that TCMs are beneficial,
particularly for mild-to-moderate cases. The efficacy of Jinhua Qinggan Granules (JHQG) in
COVID-19 patients with mild symptoms has yet to be clearly defined.
Methods: We conducted a phase 2/3, double-blind, randomized, placebo-controlled trial to
evaluate the efficacy and safety of treatment with JHQG in mild, nonhospitalized, laboratoryconfirmed COVID-19 patients. Participants were randomly assigned to receive 5g/sacket of
JHQG or placebo granules orally thrice daily for 10 days. The primary outcomes were the
improvement in clinical symptoms and proportion tested negative on viral PCR after treatment.
Secondary outcomes were the time to recovery from clinical symptoms and changes in white
blood cells (WBC) and acute phase reactants (C-reactive protein (CRP) and ferritin) 10-15 days
after treatment.
Results: A total of 300 patients were randomly assigned to receive JHQG (150 patients) and
placebo (150 patients). Baseline characteristics were similar in the two groups. In the modified
intention-to-treat analysis, JHQG showed greater clinical efficacy (82.67%) after 10 days of
treatment compared with the placebo group (10.74%) (rate difference: 71.93%; 95% CI 64.09 79.76). The proportion of patients with a negative PCR after treatment were comparable (rate
difference: -4.67%; 95% CI -15.76 - 6.42). While all changes in WBC, ferritin, and CRP levels
showed a statistically significant decline..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit